Press release 2026-11-18

AcuCort publishes November 2026 newsletter

Pharmaceutical company AcuCort has published its November 2026 newsletter. In this edition, the company highlights its recently signed exclusive licence and distribution agreement with Kye Pharmaceuticals in Canada and provides insight into the business development process behind AcuCort's international partnership agreements.

Read the newsletter
https://bit.ly/4kYh7SP

Would you like to receive future newsletters directly in your inbox? Sign up here:
https://www.acucort.se/EN/media/subscribe/

For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: +46 (0)70 365 5400
E-mail: jonas.jonmark@acucort.com

About AcuCort AB (publ)

AcuCort has developed and is commercialising Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-established corticosteroid dexamethasone. The medicine has a new, patented and user-friendly dosage form and is intended for, among other uses, the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and patients with COVID-19 who require supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway and Finland, where it is also marketed. AcuCort (ticker: ACUC) is listed on Spotlight Stock Market. For more information, visit www.acucort.se.